Beijing Bohui Innovation Technology Co Ltd Market Cap ($543.90 Million)
Market Cap & Net Worth: Beijing Bohui Innovation Technology Co Ltd (300318)
Beijing Bohui Innovation Technology Co Ltd market cap. Beijing Bohui Innovation Technology Co Ltd (SHE:300318) has a market capitalization of $543.90 Million (CN¥3.72 Billion) as of November 5, 2026. Listed on the SHE stock exchange, this China-based company holds position #11494 globally and #3200 in its home market, demonstrating a -1.73% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Beijing Bohui Innovation Technology Co Ltd's stock price CN¥4.55 by its total outstanding shares 816900495 (816.90 Million). Also see cash efficiency ratio of Beijing Bohui Innovation Technology Co L for how efficiently the company converts equity into cash flow.
Beijing Bohui Innovation Technology Co Ltd Market Cap History (2015–2026)
Beijing Bohui Innovation Technology Co Ltd market cap history from 2015 to 2026. Data shows change from $1.57 Billion to $543.90 Million (-8.00% CAGR). Check Beijing Bohui Innovation Technology Co L stock price for real-time trading data and today's change.
Beijing Bohui Innovation Technology Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Beijing Bohui Innovation Technology Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Beijing Bohui Innovation Technology Co L (300318) equity growth momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.80x
Beijing Bohui Innovation Technology Co Ltd's market cap is 0.80 times its annual revenue
Latest Price to Earnings (P/E) Ratio
73.95x
Beijing Bohui Innovation Technology Co Ltd's market cap is 73.95 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $1.57 Billion | $268.85 Million | $11.88 Million | 5.85x | 132.32x |
| 2016 | $1.08 Billion | $404.05 Million | $23.60 Million | 2.68x | 45.82x |
| 2017 | $644.78 Million | $443.75 Million | $38.85 Million | 1.45x | 16.60x |
| 2018 | $475.76 Million | $622.09 Million | $69.44 Million | 0.76x | 6.85x |
| 2019 | $488.91 Million | $628.34 Million | $2.54 Million | 0.78x | 192.28x |
| 2020 | $1.43 Billion | $738.72 Million | $7.50 Million | 1.94x | 190.52x |
| 2021 | $1.18 Billion | $714.75 Million | -$322.18 Million | 1.66x | N/A |
| 2022 | $699.30 Million | $795.93 Million | -$78.33 Million | 0.88x | N/A |
| 2023 | $745.92 Million | $1.05 Billion | -$24.93 Million | 0.71x | N/A |
| 2024 | $683.76 Million | $851.69 Million | $9.25 Million | 0.80x | 73.95x |
Competitor Companies of 300318 by Market Capitalization
Companies near Beijing Bohui Innovation Technology Co Ltd in the global market cap rankings as of November 5, 2026. Also see Beijing Bohui Innovation Technology Co L total assets for a full breakdown of the balance sheet.
Key companies related to Beijing Bohui Innovation Technology Co Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #181 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #373 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #415 globally with a market cap of $67.74 Billion USD ( AU$95.74 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #503 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #181 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $549.04 |
| #373 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $930.67 |
| #415 | CSL Ltd | AU:CSL | $67.74 Billion | AU$197.34 |
| #503 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $258.38 |
Market Capitalization of Beijing Bohui Innovation Technology Co Ltd (2015–2026)
Market capitalization of Beijing Bohui Innovation Technology Co Ltd from 2015 to today. Between 2015 and today, Beijing Bohui Innovation Technology Co Ltd's market cap moved from $1.57 Billion to $ 543.90 Million, with a yearly change of -8.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥543.90 Million | -27.43% |
| 2025 | CN¥749.50 Million | +9.62% |
| 2024 | CN¥683.76 Million | -8.33% |
| 2023 | CN¥745.92 Million | +6.67% |
| 2022 | CN¥699.30 Million | -40.97% |
| 2021 | CN¥1.18 Billion | -17.14% |
| 2020 | CN¥1.43 Billion | +192.42% |
| 2019 | CN¥488.91 Million | +2.76% |
| 2018 | CN¥475.76 Million | -26.21% |
| 2017 | CN¥644.78 Million | -40.37% |
| 2016 | CN¥1.08 Billion | -31.22% |
| 2015 | CN¥1.57 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 5th, 2026 the market cap of Beijing Bohui Innovation Technology Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $543.90 Million USD |
| MoneyControl | $543.90 Million USD |
| MarketWatch | $543.90 Million USD |
| marketcap.company | $543.90 Million USD |
| Reuters | $543.90 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Beijing Bohui Innovation Technology Co Ltd
Beijing Bohui Innovation Biotechnology Group Co., Ltd. engages in the research and development, production, sale, and after-sale service of diagnostic products in China. The company offers human immunoglobulin for rabies, tetanus, hepatitis B, and intravenous injections; albumin; human prothrombin complex; and vaccine for rabies. It also provides molecular platform, such as Automatic Real-time Fl… Read more